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Hemodialysis stimulates hepatocyte growth factor release. Studies were
performed in 26 patients on regular dialysis treatment with cuprophane
(CU), polymethylmetacrilate (PMMA) or cuprammonium (CAM) dialyz-
ers. Controls were six patients with chronic renal failure but not on regular
dialysis treatment (CRF) and six healthy subjects (N). Blood was collected
at the start (T0), and at 15 (T15) and 240 (T240) minutes of dialysis to
measure the serum hepatocyte growth factor (HGF) concentration and to
study HGF production by peripheral blood mononuclear cells (PBMC) in
vitro. The form of HGF (that is, inactive/monomeric, active/dimeric)
present in the serum was analyzed by immunoblotting. In addition, the
ability of serum to stimulate proliferation of tubular cells (HK-2) and
HGF release by PBMC and fibroblasts (MRC-5) was investigated. At T0,
serum HGF levels were identical to that of the controls. In patients treated
with CU, serum HGF rose from 0.24 ng/ml at T0 to 7.44 ng/ml at T15, and
remained high at T240. PBMC collected at T15 and T240 released signifi-
cantly more HGF in vitro than those collected at T0. Serum at T15
stimulated proliferation of HK-2 cells and the release of HGF by PBMC
and MRC-5 cells. The PMMA and CAM dialyzers had similar effects as
the CU. These results indicate that dialysis induces a striking rise in serum
HGF and a prompt circulation of factor(s) stimulating HGF release.
Dialysis-activated PBMC release HGF.
Hepatocyte growth factor (HGF) was originally identified in the
serum of partially hepatectomized rats, and was characterized as
a potent stimulator of DNA synthesis in cultured hepatocytes [1].
Subsequent studies have shown that HGF has a mitogenic action
on several other epithelial cells, including renal tubular cells [2],
and that HGF is a pleiotropic factor that induces the scattering of
cell colonies, regulates the synthesis of acute phase proteins, plays
a role in embryonic development and tumor propagation, and has
morphogenic, that is, angiogenic and tubulogenic, properties
[3–7]. Hepatocyte growth factor is produced in various organs by
cells of mesenchymal origin, such as Kupffer’s cells, lung fibro-
blasts, and mesangial cells [1, 8]. Experimental studies have shown
that tissue injury (for example, in the liver or the kidney) is
associated with a marked increase in HGF expression not only in
the injured tissue, but also in distant organs, such as lung and
spleen [9]. The humoral factors signaling tissue injury to HGF
producing cells are ill-defined substances named “injurins” [10].
Hepatocyte growth factor normally circulates as an inactive,
single-chain protein, and is converted to a mature, heterodimeric,
active form by a serine-protease homologous to Factor XII, which
in turn derives from an inactive precursor activated by thrombin.
Hepatocyte growth factor has a high degree of structural homol-
ogy with plasminogen, and urokinase type plasminogen activator
can also convert HGF into its active form [11–13].
Extracorporeal circulation in hemodialysis is associated with
leukocyte activation and the release in blood of cytokines [14].
Activated peripheral blood leukocytes are a possible source of
HGF, because HGF is produced by leukocytes in diseased liver
tissue [1]; cytokines may act as injurins [15]. Thus, dialysis may
induce the release of HGF either from activated peripheral blood
leukocytes or from tissue cells stimulated by cytokines. In addi-
tion, dialysis may cause the release of coagulation products that
convert HGF into its active form. Increased HGF activity induced
by dialysis may be pathophysiologically relevant in patients with
acute renal failure [16], or in patients on regular dialysis treatment
who have viral hepatitis. Thus, in the current study we investigated
whether hemodialysis stimulates HGF release, and whether leu-
kocytes are a source of dialysis-induced HGF.
METHODS
Patients
The study was performed in 26 patients on regular dialysis
treatment (RDT). Six patients with chronic renal failure on
conservative treatment (CRF) and six healthy subjects (N) were
used as controls. All subjects were recruited after clinical, sero-
logical and echographic exclusion of liver disease. Patients on
RDT underwent four-hour hemodialysis sessions thrice weekly
with cuprophane (CU; N 5 11), polymethylmetacrilate (PMMA;
N 5 9), or cuprammonium (CAM; N 5 6) dialyzers. Since heparin
may cause the shedding of HGF into the circulation [17], six
patients were dialyzed with CU without using heparin, that is,
extracorporeal blood coagulation was prevented by washing the
dialyzer with saline at regular intervals.
Experimental design
Blood was collected from controls after overnight fasting, and
from patients on RDT just before starting a dialysis session (T0),
at 15 minutes of dialysis (T15), and at 240 minutes of dialysis
(T240). Part of blood was immediately centrifuged and the serum
was stored at 280°C until processed for HGF measurement or
used for conditioning cell cultures; the other part was used to
isolate peripheral blood mononuclear cells (PBMC). The release
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of HGF from dialysis-activated PBMC was measured after a
48-hour incubation with 1% fetal calf serum. The ability of serum
of dialysis patients to stimulate HGF release was investigated by
conditioning PBMC of normal volunteers and human lung fibro-
blasts (MRC-5; ATCC, Rockville, MD, USA) with the serum of
patients (5% in PBMC studies, 10% in MRC-5 studies) for 48
hours, and measuring HGF in the supernatant.
Hepatocyte growth factor measurement
Hepatocyte growth factor was measured in serum and in cell
culture supernatant by a commercial EIA (R&D Systems, Min-
neapolis, MN, USA). The immunoassay uses recombinant human
HGF expressed in Sf 21 cells that produce a mixture of mono-
meric and dimeric (that is, inactive and active) HGF, and a
monoclonal antibody specific for HGF that binds with no appar-
ent preference both the monomeric and the dimeric forms.
Therefore, the immunoassay measures the sum of active and
inactive HGF.
Hepatocyte growth factor characterization
Hepatocyte growth factor is released as an inactive monomer of
92 kDa that is transformed in an active heterodimer composed of
a 69 kDa a-subunit and a 32 to 34 kDa b-subunit. The form of
HGF (that is, monomeric/inactive or dimeric/active) present in
blood was characterized by affinity purification and Western
blotting. Since coagulation products may activate HGF, experi-
ments were performed both on serum and plasma obtained by
addition of EDTA. The samples were repeatedly centrifuged in
order to eliminate all traces of clotted material. Serum and plasma
samples (about 5 ml each) were incubated for 16 hours at 4°C with
50 ml of immobilized heparin (Pierce), in the presence of 350 mM
NaCl added in order to inhibit aspecific binding. Beads were then
precipitated by centrifugation and, after three washes with PBS
(with 350 mM NaCl added), the protein samples were subjected to
SDS denaturation (5 min at 95°C in Laemmli buffer) and even-
tually separated by SDS-PAGE electrophoresis under reducing
conditions. Proteins were then transferred to nitrocellulose by
Western blotting using a semidry apparatus (Millipore). Accord-
ing to standard protocols, filters were subsequently blocked with
10% BSA-TBS and incubated with the HGF beta-chain specific
polyclonal antiserum H04, generously provided by Dr. A. Galvani
(Pharmacia-Upjohn, Milan, Italy). After incubation with HRP-
conjugated Protein-A (Amersham) and an appropriate number of
washes, chemioluminescent detection with ECL-Plus reagents
(Amersham) was eventually performed.
Serum biological activity
The ability of serum to induce the proliferation of HGF-
sensitive cells was tested using a proximal tubular cell line, derived
from normal human kidney, transfected with HPV-16 (HK-2 cells;
ATCC). Cells were grown in keratinocyte-serum free medium
(Gibco BRL, Basel, Switzerland) supplemented with recombinant
EGF (5 ng/ml; Gibco BRL) and bovine pituitary extract (40
mg/ml; Gibco BRL). Cells were plated on 96-well plates (Costar,
Bodenheim, Germany) at a density of 104 cells/well and after
24-hour incubation basal cell number/well was counted in a
NewBauer chamber; cells were then conditioned with medium
containing recombinant human HGF (3 and 10 ng/ml; Sigma), or
10% serum (control serum from normal volunteers and serum
sampled during hemodialysis at T0 and T15). Cell number/well was
Fig. 1. Effects of hemodialysis on serum hepatocyte growth factor (HGF)
concentration. Columns are means, bars are SD. Abbreviations are: CU,
cuprophane dialyzer; PMMA, polymethylmetacrilate dialyzer; CAM, cu-
prammonium dialyzer. T0, T15 and T240 indicate timing of blood samples,
just before starting dialysis, at 15 minutes of dialysis, and at 240 minutes
of dialysis, respectively. **P , 0.001 and *P , 0.01 versus T0.
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counted again after 24 and 48 hours. Cell viability (Trypan Blue
test) was . 99%.
The ability of serum to induce HGF release was tested on
PBMC (see PBMC preparation below) and fibroblasts. Human
lung fibroblasts (MRC-5; ATCC) were grown in Eagle’s minimum
essential medium with 2 mM l-glutamine and Earle’s BSS (ATCC)
with 1.5 g/liter NaHCO3, 0.1 mM nonessential amino acids and 1
mM sodium pyruvate, supplemented with 10% FCS (ATCC). At
passage 19, cells were seeded on 24-well plates (Costar) at a
density of 105 cells/well and incubated with 10% FCS, or 10%
human serum (from normal volunteers and hemodialysis pa-
tients). Supernatant was collected for HGF measurement after 48
hours of incubation.
Peripheral blood mononuclear cell preparation and culture
Platelets are a potential source of HGF [1], and we showed in
preliminary experiments that platelets contaminate PBMC ob-
tained by gradient centrifugation (120,000 to 160,000 platelets/ml
in a final suspension of 2 z 106 PBMC/ml). Therefore, we tested
whether platelets, cultured in the same conditions as PBMC,
release HGF. Blood (16 ml) was mixed with an ACD anticoagu-
lant solution (4 ml; Baxter) and centrifuged for 10 minutes at
1,200 rpm. The platelet-rich supernatant was washed twice with
PBS 1 EDTA (0.3 mM/liter) and centrifuged for 15 minutes at
1,400 rpm. Platelets, separated in the final pellet, were resus-
pended in Iscove’s medium (800,000 platelets/ml) with 1% fetal
calf serum (FCS) or the serum of patients (5%) for 48 hours, and
HGF was measured in the supernatant.
We have described methods of PBMC culture in detail previ-
ously [14]. Briefly, PBMC were separated by standard Ficoll-
Hypaque gradient centrifugation and cultured in suspension (2 z
106/ml) for 48 hours in Iscove’s (Flow Laboratories) containing
100 IU/ml penicillin and 100 mg/ml streptomycin, and 1% de-
complemented FCS or 5% serum of patients and controls. Flow
cytometry of PBMC yielded 80 to 83% lymphocytes, 11 to 12%
monocytes, and 4 to 6% neutrophils. Cell viability was tested by
the Trypan Blue exclusion test and yielded 96 to 98% viable cells.
Statistics
Analysis of variance by ANOVA and Newman-Keuls test were
used for comparison of the means.
RESULTS
Effects of dialysis on serum hepatocyte growth factor
At T0, HGF averaged 0.24 6 0.19 SD ng/ml and was not
significantly different from the mean value in patients with CRF
(0.19 6 0.08 SD ng/ml) and normal volunteers (0.15 6 0.10 SD
ng/ml). The effects of dialysis on serum concentration of HGF are
shown in Figure 1. In patients treated with Cuprophane dialyzers,
HGF rose strikingly to 7.44 ng/ml at T15 and remained 15 times
higher than T0 at T240. In patients treated with PMMA and CAM
HGF levels increased similarly to the patients treated with CU. A
marked rise in HGF occurred independently of the use of heparin
(Fig. 2); however, the peak serum HGF concentration was
significantly higher (P , 0.05) in the standard dialysis versus the
no-heparin dialysis.
Characterization of hepatocyte growth factor
Figure 3 shows Western blot analysis performed on serum.
Results obtained on plasma were overlapping. Before starting
dialysis (lane A) a weak band of pro-HGF (92 kDa) is detectable
and no b-chain is visible. At T15 (lane B) pro-HGF is markedly
increased and two intense bands of b-chain (32 and 34 kDa; the
two forms are differently glycosilated) are clearly evident. Note
the greater amount of the 32 kDa form. At T240 (lane C) serum
level of pro-HGF is still higher than at T0, and a weak signal
allows detection of only the lower band of the b-chain.
Fig. 2. Effect of no-heparin dialysis on serum concentration of hepato-
cyte growth factor (HGF). Columns are means, and bars are SD. Abbre-
viations are in the Figure 1 legend. *P , 0.01 versus T0.
Fig. 3. Western blot analysis of hepatocyte growth factor (HGF). Lane A
indicates the basal serum level of HGF; lane B shows the serum level of
HGF after 15 minutes of dialytic treatment; lane C shows serum level of
HGF after 240 minutes of dialytic treatment.
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Effects of dialysis on peripheral blood mononuclear cells
Hepatocyte growth factor in the supernatant of PBMC isolated
from dialysis patients at T0 averaged 0.11 6 0.11 SD ng/ml, a value
that was not significantly different from HGF released by PBMC
isolated from normal volunteers (0.07 6 0.06 SD ng/ml, P . 0.05).
However, as shown in Figure 4, dialysis with all of the tested
membranes strongly stimulated PBMC to release HGF. In fact,
the HGF concentration in supernatant of PBMC collected at T15
and T240 was much higher than in the supernatant of PBMC
collected at T0. Hepatocyte growth factor was not released by
platelets contaminating PBMC, because the result of EIA per-
formed on supernatant of platelets cultured in the same condi-
tions as PBMC was not different from zero, that is, from that
performed on blank culture medium.
Tubular cell proliferation assay
As shown in Figure 5, the addition of recombinant HGF to
culture medium of HK-2 cells caused a dose- and time-dependent
increase in cell number. An addition of T15 serum caused a rise in
cell number that was significantly higher than the increase caused
by normal serum and T0 serum; the difference was significant both
at 24 and at 48 hours. Note that the HGF concentration in T15
serum was 7 ng/ml and that the rise in cell number occurring with
this serum was half way between that occurring with 3 and 10
ng/ml of recombinant HGF.
Effects of serum on hepatocyte growth factor release by
peripheral blood mononuclear cells and fibroblasts
The release of HGF from PBMC of normal volunteers cultured
with serum of normal volunteers averaged 0.06 6 0.03 SD ng/ml
and did not differ from the amount of HGF produced by PBMC
cultured with the serum of dialysis patients collected at T0 (0.11 6
0.09 SD ng/ml). In contrast, serum collected at T15 and T240 caused
a HGF release. In fact, after subtracting the HGF that was in the
serum, the HGF supernatant concentrations were significantly
higher in cultures treated with T15 and T240 serum than in cultures
treated with T0 serum. The phenomenon occurred independently
of the type of membrane used for dialysis (Fig. 6).
The effects of serum on fibroblasts are shown in Figure 7. The
HGF concentrations in the supernatant of cells conditioned with
normal serum and serum collected at T0 were similar, while it was
significantly increased in the supernatant of cells treated with
serum collected at T15.
DISCUSSION
The present study shows that hemodialysis causes a prompt and
prolonged release of HGF into the circulation, raising HGF
serum concentration up to 30 times. The release of HGF takes
place even if dialysis is performed without heparin, so that it does
not depend on heparin-induced shedding of receptor-bound HGF
from peripheral tissues.
Hepatocyte growth factor normally circulates as a pro-HGF
that is converted into an active form by zymogens homologous to
coagulation factors. Usually this conversion occurs in injured
tissues, where the zymogens that transform pro-HGF are in turn
activated from inactive precursors. As shown by our Western blot
analysis, pro-HGF released during dialysis is rapidly and largely
activated. In fact, 15 minutes after starting treatment a large
amount of both monomeric and dimeric HGF is present in serum,
and the presence of dimeric HGF is associated with a mitogenic
Fig. 4. Hepatocyte growth factor (HGF) release from peripheral blood
mononuclear cells (PBMC) of dialysis patients. Columns are means, and
bars are SD. Abbreviations are in the legend to Figure 1. **P , 0.01 and
*P , 0.05 versus T0.
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activity of serum on renal tubular cells in vitro. At the end of
dialysis the amount of pro-HGF is still much greater than in basal
conditions, while active HGF is barely detectable. Our study does
not clarify whether this decay of active HGF is due to receptor
binding and deposition in peripheral tissues, or to reduced serum
zymogen activity. However, the increased availability of circulat-
ing HGF, even in its inactive form, is biologically relevant since
HGF may be activated in injured sites, for example, in the kidney
in patients with acute tubular necrosis, or in the liver in patients
with hepatitis.
Serum HGF peaks early after the start of extracorporeal
circulation, in parallel with dialysis-induced leukocyte activation
[18], suggesting that leukocytes participate in releasing HGF.
Until now, the ability of circulating leukocytes to produce HGF
has not been proven, but HGF is expressed in leukocytes infil-
trating inflamed liver, and cells with monocyte/macrophage phe-
notype produce HGF in culture [19]. These observations
prompted us to study the production of HGF by PBMC activated
by dialysis. Our in vitro experiments show that PBMC collected
during dialysis release much more HGF than PBMC collected
before starting dialysis, indicating that: (a) PBMC are actually
able to produce HGF and (b) dialysis stimulates HGF production
by PBMC. In theory, platelets contaminating PBMC might be the
source of HGF measured in PBMC culture supernatant [20].
However, we have cultured highly enriched platelets under the
same conditions as PBMC have shown that they do not produce
HGF. Therefore, our findings definitely demonstrate that dialysis
induces HGF production from PBMC. PBMC stimulation occurs
promptly, that is, within 15 minutes of dialysis, and persists
throughout the dialysis session.
Experimental models of acute tissue damage have shown that
HGF production is induced by substances named “injurins,”
which are released from injured organs into the circulation.
Injurins released from an injured site induce HGF production in
distant, undamaged organs (liver, kidney, spleen), which act to
accelerate tissue repair [9]. Therefore, we investigated whether
injurin-like factors account for HGF production during dialysis.
Having shown that PBMC taken during dialysis produce HGF, we
used PBMC collected from normal volunteers to test injurin-like
activity in the serum of dialysis patients. Our in vitro studies clearly
indicate that a PBMC stimulating factor appears in serum after 15
minutes of dialysis and is still present at the end of treatment. In
fact, serum collected at 15 and 240 minutes of dialysis is effective
in inducing HGF production from PBMC, while serum collected
before dialysis and from the serum of normal volunteers are not
effective. In addition, we tested the ability of serum collected
during dialysis to stimulate the release of HGF from fibroblasts,
that is, cells normally present in solid organs. Our observation that
serum sampled at 15 minutes of dialysis causes HGF production
by fibroblasts suggests that, in addition to PBMC, internal organs
stimulated by a circulating factor(s) produce HGF during dialysis.
We have not investigated the nature of the factors circulating
during dialysis that cause the HGF release. A specific injurin with
molecular mass of 10 to 20 kDa has been purified in rat serum
[10], but injurins are a heterogeneous and ill-defined class of
Fig. 5. Effects of recombinant hepatocyte
growth factor (HGF) and of serum on
proliferation of proximal tubular cells HK-2.
Columns represent the average change in cell
number/well at (M) 24 hours and (f) 48 hours,
and bars are SD. *P , 0.001 versus normal
serum and T0 serum at 24-hours of incubation.
EP , 0.001 versus normal serum and T0 serum
at 24- and 48-hours of incubation.
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substances, possibly different in distinct pathophysiological con-
ditions. Since cytokines like interleukin-1 (IL-1) and tumor ne-
crosis factor (TNF) have been shown to induce HGF production,
and hemodialysis causes the release of these and other cytokines
from activated leukocytes [14, 21], we suggest that cytokines may
act as injurins in the serum of dialysis patients. Should cytokines
released by PBMC behave as injurins, during dialysis leukocytes
would play a double role as both direct producers of HGF and
inducers of its production in tissues. In conclusion, we have shown
that hemodialysis causes the release of factors that stimulate HGF
production from PBMC, and possibly solid organs. PBMC acti-
vated by dialysis are a possible source of these factors (cytokines),
but our study findings do not permit any conclusions about their
origin and exact nature, nor information on the mechanisms that
cause their release. Interestingly, activation of the HGF-releasing
factor(s)/HGF system is not peculiar to cellulosic membranes. It
also occurs with so-called biocompatible membranes, which im-
plies that it does not depend on phenomena causing dialysis-
associated leukopenia, that is, complement activation and in-
creased expression of leukocyte adhesion molecules [22].
The increased HGF production caused by dialysis deserves
consideration for several reasons. First, HGF is a pleiotropic
substance that causes the proliferation of several cell types
including fibroblasts, scattering of cells, angiogenesis, arrange-
ment of cells in complex structures (for example, tubular), and
participates in inflammatory phenomena. Although many of
HGF’s actions concur to tissue regeneration and repair, adverse
effects of continued HGF stimulation are possible, for example, in
Fig. 6. Hepatocyte growth factor (HGF) release from peripheral blood
mononuclear cells (PBMC) of normal volunteers conditioned with serum
of dialysis patients. Columns are the average concentration of HGF in
supernatant after subtraction of HGF added with serum. Bars are SD.
Abbreviations are in the legend to Figure 1. *P , 0.01 versus T0.
Fig. 7. Effects of serum on hepatocyte growth factor (HGF) release by
fibroblasts in culture. Columns represent the average concentration of
HGF in supernatant after subtraction of HGF added with serum. Bars are
SD. *P , 0.001 versus normal serum and T0 serum.
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the mobilization and proliferation of tumoral cells or induction of
exaggerated fibrosis in inflamed tissues. Thus, the production of
HGF should be taken into account in evaluating the biocompat-
ibility of dialysis. Second, hemodialyis is often required to treat
patients with toxic-ischemic acute renal failure (ARF), and exper-
imental and clinical observations indicate that HGF plays an
important role in recovery from this disease [19, 23]. Thus, dialysis
techniques or schedules may be tailored to sustain HGF produc-
tion in patients with ARF. Third, experimental and clinical studies
suggest that HGF is a protective factor in patients with viral
hepatitis [24]. In view of the high prevalence of viral hepatic
infections in dialysis patients, the regular attainment of “pharma-
cological” serum HGF levels in these patients is a model to study
the effect on hepatitis of HGF and to test its therapeutic efficacy.
Finally, hemodialysis represents a repetitive and reproducible
condition of activation of HGF and may be a useful model to
further investigate its pathophysiology.
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APPENDIX
Abbreviations used in this article are: ARF, acute renal failure; CAM,
cuprammonium; CRF, patients with chronic renal failure who are not on
regular dialysis treatment; CU, cuprophane; FCS, fetal calf serum; HGF,
hepatocyte growth factor; HK-2 cells, proximal tubular cell line; MRC-5,
human lung fibroblasts; N, healthy subjects; PBMC, peripheral blood
mononuclear cells; PMMA, polymethylmetacrilate; RDT, regular dialysis
treatment.
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